Grufity logoGrufity logo

VCYT

26.20USD-0.22(-0.83%)Market Closed

Veracyte Inc

Market Summary

USD26.20-0.22Market Closed
-0.83%

VCYT Alerts

VCYT Stock Price

RSI Chart

Valuation

Market Cap

1.4B

Price/Earnings

-28.41

Price/Sales

5.15

Price/Cashflow

-633.42

MarketCap/EBT

-27.18

Price/Sales

Profitability

Operating Margin

83.57%

EBT Margin

-18.95%

Return on Equity

-4.57%

Return on Assets

-4.25%

Fundamentals

Revenue

Revenue (TTM)

268.4M

Revenue Y/Y

32.23%

Revenue Q/Q

7.5%

Earnings

Earnings (TTM)

-48.6M

Earnings Y/Y

-5.47%

Earnings Q/Q

34.08%

Price Action

52 Week Range

14.8545.58
(Low)(High)

Last 7 days

0.9%

Last 30 days

42.7%

Last 90 days

22.8%

Trailing 12 Months

-37.9%

Financial Health

Current Ratio

3.96

Investor Care

Shares Dilution (1Y)

6.08%

Diluted EPS (TTM)

-0.67

Peers (Alternatives to Veracyte)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
4.66% 39.76%
20.65
4.55
4.80% 77.95%
81.0B
14.2B
0.31% 13.58%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
0.58% 68.05%
24.61
9.26
22.03% 50.41%
16.6B
3.3B
6.30% 17.26%
17.56
5
22.05% 63.88%
MID-CAP
4.6B
776.0M
-18.88% -60.89%
-8.03
6.39
37.38% -33.90%
3.8B
249.9M
-9.95% -60.16%
-24.67
15.19
132.20% -22.25%
SMALL-CAP
1.4B
268.4M
42.70% -37.93%
-28.41
5.15
70.42% 22.87%
1.1B
314.9M
-35.01% -70.93%
-15.26
3.36
24.16% -675.60%
616.1M
123.7M
-4.32% -52.59%
-13.85
5.59
43.31% -77.98%
555.2M
520.0M
12.10% -84.71%
-0.18
1.11
19.60% -686.73%
431.9M
463.2M
-15.24% -73.45%
5.91
0.94
3.79% -0.40%
153.0M
-
-12.62% -45.45%
-4.99
-
- -39.92%
9.1M
3.3M
-5.26% -89.09%
-0.36
2.22
-21.77% 4.40%

Financials for Veracyte

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue7.1%268251220187157
  S&GA Expenses5.0%9287807160
  R&D Expenses9.3%3734302420
Earnings Before Taxes-0.9%-50.86-50.40-81.60-78.38-67.02
Net Income-1.0%-48.65-48.16-75.56-73.08-63.07
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-2.5%1,1441,1741,1881,1861,027
  Current Assets-1.4%235238243229371
    Cash Equivalents-6.2%153164173164328
  Inventory18.0%151211107
  Net PPE27.8%1512---
  Goodwill-2.0%690704708714472
Liabilities-9.4%8088917956
  Current Liabilities-5.1%5963645036
    LT Debt, Current5.0%111--
    LT Debt, Non Current-100.0%-11--
Shareholder's Equity-1.9%1,0641,0851,0971,107971
  Retained Earnings-2.6%-381.15-371.62-357.16-346.63-332.50
  Additional Paid-In Capital0.4%1,4831,4771,4691,4621,304
Accumulated Depreciation-21----
Shares Outstanding0.2%7271717167
Float-2,700----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-3308.8%-2.180-31.62-37.81-34.66
  Share Based Compensation7.4%2725231915
Cashflow From Investing-6.5%-176.83-166.05-739.21-740.48-576.66
Cashflow From Financing-27.3%57596599793

Risks

What is the probability of a big loss on VCYT?

100%


Probability that Veracyte stock will be more than 20% underwater in next one year

70.4%


Probability that Veracyte stock will be more than 30% underwater in next one year.

42.7%


Probability that Veracyte stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VCYT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Veracyte was unfortunately bought at previous high price.

Returns

Cumulative Returns on VCYT

20.0%


7-Year Cumulative Returns

32.5%


5-Year Cumulative Returns

-3.4%


3-Year Cumulative Returns

What are the long-term rolling returns for VCYT?

FIve years rolling returns for Veracyte.

Which funds bought or sold VCYT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
Capital Impact Advisors, LLC
NEW
-
103,000
103,000
0.10%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-330,000
1,490,000
-%
2022-11-17
M&T Bank Corp
-
-
-203,000
531,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-12,000
-
-%
2022-11-15
MERCER GLOBAL ADVISORS INC /ADV
ADDED
439.02
849,000
1,092,000
0.01%
2022-11-15
ALLIANCEBERNSTEIN L.P.
UNCHANGED
-
-257,000
1,293,000
-%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
2,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
FRED ALGER MANAGEMENT, LLC
SOLD OFF
-100
-258,000
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
600.19
1,743,610
2,103,800
-%

1–10 of 46

Latest Funds Activity

Are funds buying VCYT calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own VCYT

Veracyte News

Stocks Register

Analysts Provide Their Views On Veracyte Inc. (VCYT).25 hours ago

Value the Markets

VCYT Fair Value

Recent SEC filings of Veracyte

View All Filings
Date Filed Form Type Document
Nov 15, 2022
4
Insider Trading
Nov 15, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 03, 2022
10-Q
Quarterly Report
Nov 02, 2022
8-K
Current Report
Oct 17, 2022
4
Insider Trading
Sep 07, 2022
4
Insider Trading
Sep 07, 2022
4
Insider Trading
Sep 07, 2022
4
Insider Trading
Sep 07, 2022
4
Insider Trading

Latest Insider Trading transactions for VCYT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-11
JONES EVAN/ FA
SOLD
-181,357
30.2262
-6,000
-
2022-11-11
Kennedy Giulia C
ACQUIRED
28.68
14.34
2
Chief Scientific & Med Officer
2022-11-11
Kennedy Giulia C
SOLD
-58.68
29.34
-2
Chief Scientific & Med Officer
2022-11-04
Kennedy Giulia C
SOLD
-25,575
25
-1,023
Chief Scientific & Med Officer
2022-10-13
Anderson Bonnie H
ACQUIRED
99,996
9.0184
11,088
Executive Chairwoman
2022-09-02
Kennedy Giulia C
SOLD (Taxes)
-19,333.4
19.18
-1,008
Chief Scientific & Med Officer
2022-09-02
Chambers Rebecca
SOLD (Taxes)
-57,981.1
19.18
-3,023
Chief Financial Officer
2022-09-02
Anderson Bonnie H
SOLD (Taxes)
-39,165.6
19.18
-2,042
Executive Chairwoman
2022-09-02
Stapley Marc
SOLD (Taxes)
-19,410.2
19.18
-1,012
Chief Executive Officer
2022-08-09
Barr Eliav
ACQUIRED
-
-
20,721
-

1–10 of 50

VCYT Income Statement

2022-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Total revenue$ 75,592$ 60,370$ 216,239$ 152,178
Operating expenses:    
Research and development10,7738,00629,31619,591
Selling and marketing25,67821,67073,43357,628
General and administrative17,60020,74958,31082,504
Intangible asset amortization5,2134,98316,09010,507
Total operating expenses85,27277,051251,900221,748
Loss from operations(9,680)(16,681)(35,661)(69,570)
Other income (loss), net8051,2022,675(762)
Loss before income taxes(8,875)(15,479)(32,986)(70,332)
Income tax benefit(152)(1,350)(270)(5,297)
Net loss$ (8,723)$ (14,129)$ (32,716)$ (65,035)
Net loss per common share, basic (in USD per share)$ (0.12)$ (0.20)$ (0.46)$ (0.97)
Net loss per common share, diluted (in USD per share)$ (0.12)$ (0.20)$ (0.46)$ (0.97)
Shares used to compute net loss per common share, basic (in shares)71,656,69469,743,73371,456,00866,820,654
Shares used to compute net loss per common share, diluted (in shares)71,656,69469,743,73371,456,00866,820,654
Testing revenue    
Revenue:    
Total revenue$ 64,577$ 50,897$ 180,275$ 134,768
Operating expenses:    
Cost of revenue19,81616,07355,92342,494
Product revenue    
Revenue:    
Total revenue3,3142,9599,4018,706
Operating expenses:    
Cost of revenue1,9811,4915,2024,304
Biopharmaceutical and other revenue    
Revenue:    
Total revenue7,7016,51426,5638,704
Operating expenses:    
Cost of revenue$ 4,211$ 4,079$ 13,626$ 4,720

VCYT Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 170,112,000$ 173,197,000
Short-term investments03,964,000
Accounts receivable40,068,00041,461,000
Supplies and inventory13,798,00011,225,000
Prepaid expenses and other current assets14,538,00013,255,000
Total current assets238,516,000243,102,000
Property and equipment, net17,237,00015,098,000
Right-of-use assets, operating leases13,885,00016,043,000
Intangible assets, net176,542,000202,731,000
Goodwill676,885,000707,904,000
Restricted cash749,000749,000
Other assets2,143,0002,198,000
Total assets1,125,957,0001,187,825,000
Current liabilities:  
Accounts payable11,114,00012,360,000
Accrued liabilities32,137,00039,475,000
Current portion of long-term debt1,187,0001,127,000
Current portion of deferred revenue3,863,0004,646,000
Current portion of acquisition-related contingent consideration5,913,0002,682,000
Current portion of operating lease liabilities3,958,0003,630,000
Current portion of other liabilities180,000231,000
Total current liabilities58,352,00064,151,000
Deferred revenue, net of current portion0343,000
Deferred tax liabilities4,342,0005,592,000
Acquisition-related contingent consideration, net of current portion2,411,0005,722,000
Operating lease liabilities, net of current portion11,527,00014,096,000
Other liabilities1,148,0001,407,000
Total liabilities77,780,00091,311,000
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of September 30, 2022 and December 31, 202100
Common stock, $0.001 par value; 125,000,000 shares authorized, 71,741,517 and 71,123,108 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively72,00071,000
Additional paid-in capital1,492,044,0001,468,683,000
Accumulated deficit(389,873,000)(357,157,000)
Accumulated other comprehensive loss(54,066,000)(15,083,000)
Total stockholders’ equity1,048,177,0001,096,514,000
Total liabilities and stockholders’ equity$ 1,125,957,000$ 1,187,825,000